Certain advantages of Scopus compare with Web of Science in a bibliometric analysis related to smoking

El objetivo de este trabajo es comparar entre Web of Science (WoS) y Scopus los indicadores bibliométricos básicos del área de tabaquismo de autores españoles en el período 2000-2009. Métodos: La búsqueda se realizó en el SCI-Expanded y Scopus (“smok*” OR “tobac*”). Resultados: La media total anual del nº de documentos fue de 41 ± 12 para WoS vs 60 ± 16 en Scopus (p = 0,007). Aumento progresivo del índice de colaboración. La media anual del índice de colaboración fue de 9,41 ± 2,73 en WoS vs 7,12 ± 1,52 en Scopus (p = 0,029). Mayor número de citas con el paso del tiempo en ambas bases de datos pero son más recientes las citas en Scopus, el índice citas/artículo fue mayor en WoS (WoS 14,47 vs 11,50 Scopus). Conclusiones: Mayor número de revistas, trabajos, firmas y citas en Scopus comparado con WoS. El índice firmas/artículo e instituciones/artículo fue mayor en WoS. Incremento del índice de colaboración y mayor acúmulo de citas en los artículos más antiguos, pero más recientes en ScopusObjective: To compare basic bibliometric indicators on the topic of smoking by Spanish authors in Web of Science (WoS) and Scopus (2000 to 2009). Methods: The search was performed in SCI-Expanded and Scopus (key words “smok*” OR “tobac*”). Results: Total annual mean of documents was 41 ± 12 for WoS vs 60 ± 16 for Scopus (p = 0.007). The collaboration index (CI) increased during the study period in both databases. The CI annual mean was 9.41 ± 2.73 in WoS vs 7.12 ± 1.52 in Scopus (p = 0.029). The number of citations rose over time in both databases, but citations were more recent in Scopus, although the citation/articles index was higher in WoS (14,47 vs 11,50). Conclusions: We found a higher number of journals, articles, signing authors and total citations in Scopus, but the signing authors/articles and institutions/articles indices were higher in WoS. The CI increased annually during the study period in both databases (the CI annual mean was higher in WoS). Citations were higher for older articles but more recent in Scopus (citation/articles index was higher in WoS

Vacuna antinicotínica

Introducción: La dependencia a las sustancias de abuso constituye uno de los mayores problemas de saludpública en todo el mundo. El desarrollo de una vacuna contra la nicotina sugiere que en el futuro la inmunizaciónpodría ser una estrategia eficaz para el tratamiento y la prevención del tabaquismo. Materiales y Métodos: Lasvacunas desarrolladas actuarían uniéndose a las moléculas de nicotina en la sangre, previniendo así ladistribución de ésta al cerebro del fumador. Resultados: Tres son las vacunas desarrolladas en la actualidady en fase I de la investigación: NicVax, TA – NIC y NIC – Qb. Conclusiones: Los resultados obtenidos hasta ahorademuestran que la vacuna antinicotinica es segura, bien tolerada y genera una adecuada respuesta inmunológicacontra la nicotina, siendo su futuro prometedor. PALABRAS CLAVE: Tabaquismo. Nicotina. Vacuna. Anticuerpos

Factors associated with smoking among tuberculosis patients in Spain

Altres ajuts: This work was made possible by a grant from the Spanish Society of Pneumology and Thoracic Surgery, SEPAR 2011.To determine the prevalence of smoking and analyze associated factors in a cohort of patients diagnosed with tuberculosis (TB) in Spain between 2006 and 2013. Multicenter, cross-sectional, descriptive, observational study using a national database of TB patients, using logistic regression to calculate odds ratios (OR) and confidence intervals (CI). We analyzed 5,846 cases (62 % men, mean age 39 years, 33 % foreigners). 23.4 % were alcohol abuser, 1.3 % were injected drug users (IDU), 4.6 % were co-infected with HIV, and 7.5 % had a history of TB treatment. 6.6 % and 0.8 % showed resistance to one and multiple drugs, respectively. The predominant clinical presentation was pulmonary (71 %) with a cavitary radiological pattern in 32.8 % of cases. 82 % of cases were confirmed microbiologically, and 54 % were smear-positive microscopy. 2,300 (39.3 %) patients were smokers. The following factors were associated with smoking: male sex (OR = 2.26;CI:1.97;2.60), Spanish origin (OR = 2.79;CI:2.40-3.24), alcoholism (OR = 2.85;CI:2.46;3.31), IDU (OR = 2.78;CI:1.48;5.52), homelessness (OR = 1.99;CI:1.14-3.57), pulmonary TB (OR = 1.61;CI:1.16;2.24), cavitary radiological pattern (OR = 1.99;CI:1.43;2.79) and a smear-positive microscopy at the time of diagnosis (OR = 1.39;CI:1.14;1.17). The prevalence of smoking among TB patients is high. Smokers with TB have a distinct sociodemographic, clinical, radiological and microbiological profile to non-smokers

Assessment of the influence of direct tobacco smoke on infection and active TB management

Smoking is a risk factor for tuberculosis (TB) infection and disease progression. Tobacco smoking increases susceptibility to TB in a variety of ways, one of which is due to a reduction of the IFN-γ response. Consequently, an impaired immune response could affect performance of IFN-γ Release Assays (IGRAs).Miguel Servet program of the Instituto de Salud Carlos III (Spain). ML was supported by a joint ERS/SEPAR fellowship (LTRF 2015). The research was partially supported by a grant from the Instituto de Salud Carlos III (PI 13/01546 and PI 16/01912), integrated in the Plan Nacional de I+D+I and cofunded by the ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); and a grant from the Sociedad Española de Neumología y Cirugía Torácica (SEPAR; Barcelona, Spain) (Smoking Integrated Research Programme Call) to NA

Factors associated with smoking among tuberculosis patients in Spain

BACKGROUND: To determine the prevalence of smoking and analyze associated factors in a cohort of patients diagnosed with tuberculosis (TB) in Spain between 2006 and 2013. METHODS: Multicenter, cross-sectional, descriptive, observational study using a national database of TB patients, using logistic regression to calculate odds ratios (OR) and confidence intervals (CI). RESULTS: We analyzed 5,846 cases (62 % men, mean age 39 years, 33 % foreigners). 23.4 % were alcohol abuser, 1.3 % were injected drug users (IDU), 4.6 % were co-infected with HIV, and 7.5 % had a history of TB treatment. 6.6 % and 0.8 % showed resistance to one and multiple drugs, respectively. The predominant clinical presentation was pulmonary (71 %) with a cavitary radiological pattern in 32.8 % of cases. 82 % of cases were confirmed microbiologically, and 54 % were smear-positive microscopy. 2,300 (39.3 %) patients were smokers. The following factors were associated with smoking: male sex (OR = 2.26;CI:1.97;2.60), Spanish origin (OR = 2.79;CI:2.40–3.24), alcoholism (OR = 2.85;CI:2.46;3.31), IDU (OR = 2.78;CI:1.48;5.52), homelessness (OR = 1.99;CI:1.14–3.57), pulmonary TB (OR = 1.61;CI:1.16;2.24), cavitary radiological pattern (OR = 1.99;CI:1.43;2.79) and a smear-positive microscopy at the time of diagnosis (OR = 1.39;CI:1.14;1.17). CONCLUSIONS: The prevalence of smoking among TB patients is high. Smokers with TB have a distinct sociodemographic, clinical, radiological and microbiological profile to non-smokers

Smoker, Former Smoker and COVID-19: Nicotine Does Not Protect Against SARS-CoV-2

Queremos agradecer a Moril et al.1 el interés en nuestro trabajo, pues nos permite reflexionar sobre el tema. La proteína Spike del SARS-CoV-2 es la responsable de facilitar su entrada a las células humanas, requiriendo cebado por la proteasa TMPRSS2 que permite la fusión de las membranas viral y celular2. El receptor utilizado por la proteína Spike es la enzima convertidora de angiotensina 2 (ACE2)2, que se expresa en diferentes estirpes celulares, además de en el pulmón; existiendo, a nivel pulmonar, un gradiente de expresión de ACE2 (mayor expresión en vías respiratorias superiores [epitelio nasal] y menor en los neumocitos alveolares)2. Se sugiere que una mayor expresión de ACE2 podría contribuir a una aumentada infectividad viral por SARS-CoV-22.Peer reviewe